| Literature DB >> 23782650 |
Rachel Balder1, Teresa L Shaffer, Eric R Lafontaine.
Abstract
BACKGROUND: Moraxella catarrhalis is a human-specific gram-negative bacterium readily isolated from the respiratory tract of healthy individuals. The organism also causes significant health problems, including 15-20% of otitis media cases in children and ~10% of respiratory infections in adults with chronic obstructive pulmonary disease. The lack of an efficacious vaccine, the rapid emergence of antibiotic resistance in clinical isolates, and high carriage rates reported in children are cause for concern. Virtually all Moraxella catarrhalis isolates are resistant to β-lactam antibiotics, which are generally the first antibiotics prescribed to treat otitis media in children. The enzymes responsible for this resistance, BRO-1 and BRO-2, are lipoproteins and the mechanism by which they are secreted to the periplasm of M. catarrhalis cells has not been described.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23782650 PMCID: PMC3695778 DOI: 10.1186/1471-2180-13-140
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Schematic representation of the locus. The relative position of tat-specific oligonucleotide primers (P1-P8) used throughout the study is shown (see Methods section for details).
Figure 2Growth of the WT isolate O35E and mutant strains in liquid medium. Plate-grown bacteria were used to inoculate sidearm flasks containing 20-mL of broth to an optical density (OD) of ~50 Klett units. The cultures were then incubated with shaking at a temperature of 37°C for seven hours. The OD of each culture was determined every 60-min using a Klett Colorimeter. Results are expressed as the mean OD ± standard error (Panel A). Aliquots (1-mL) were taken out of each culture after recording the OD, diluted, and spread onto agar plates to determine the number of viable colony forming units (CFU). Results are expressed as the mean CFU ± standard error (Panel B). Growth of the wild-type (WT) isolate O35E is compared to that of its tatA (O35E.TA), tatB (O35E.TB), and tatC (O35E.TC) isogenic mutant strains carrying the control plasmid pWW115. Asterisks indicate a statistically significant difference in the growth rates of mutant strains compared to that of the WT isolate O35E.
Figure 3Growth of the WT isolate O35E and mutant strains in liquid medium. Plate-grown bacteria were used to inoculate sidearm flasks containing 20-mL of broth to an OD of 50 Klett units. The cultures were then incubated with shaking at a temperature of 37°C for seven hours. The OD of each culture was determined every 60-min using a Klett Colorimeter. Panel A: Growth of O35E is compared to that of its tatA isogenic mutant strain, O35E.TA, carrying the plasmid pWW115 (control), pRB.TatA (specifies a WT copy of tatA), and pRB.TAT (harbors the entire tatABC locus). Panel B: Growth of O35E is compared to that of its tatB isogenic mutant strain, O35E.TB, carrying the plasmid pWW115, pRB.TatB (specifies a WT copy of tatB), and pRB.TAT. Panel C: Growth of O35E is compared to that of its tatC isogenic mutant strain, O35E.TC, carrying the plasmid pWW115 and pRB.TatC (contains a WT copy of tatC). Growth of the bro-2 isogenic mutant strain O35E.Bro is also shown. Results are expressed as the mean OD ± standard error. Asterisks indicate a statistically significant difference in the growth rates of mutant strains compared to that of the WT isolate O35E.
Figure 4Features of the BRO-2 signal sequence. The M. catarrhalis ATCC43617 bro-2 gene product was analyzed using the SignalP 4.0 server. Panel A: The first 30 amino acid of BRO-2 are shown. Residues 1–26 specify characteristics of a prokaryotic signal sequence, specifically neutral (n, highlighted in yellow), hydrophobic (h, highlighted in blue) and charged (c, highlighted in red) regions. The highly-conserved twin-arginine recognition motif is bolded and underlined. Panel B: Features of a typical TAT signal sequence where x represents any amino acid (adapted from [59]). The arrowheads indicate signal peptidase cleavage sites.
Figure 5Growth of the WT isolate O35E and mutant strains in the presence of the β-lactam antibiotic carbenicillin. The ability of tat mutants to grow in the presence of carbenicillin (cab) was tested by spotting equivalent numbers of bacteria onto Todd-Hewitt agar plates supplemented with the antibiotic (TH + cab). As control, bacteria were also spotted onto agar plates without carbenicillin (TH). These plates were incubated for 48 hrs at 37°C to accommodate the slower growth rate of the tat mutants. Panel A: Growth of O35E is compared to that of its tatA isogenic mutant strain, O35E.TA, carrying the plasmid pWW115 (control), pRB.TatA (specifies a WT copy of tatA), and pRB.TAT (harbors the entire tatABC locus). Panel B: Growth of O35E is compared to that of its tatB isogenic mutant strain, O35E.TB, carrying the plasmid pWW115, pRB.TatB (specifies a WT copy of tatB), and pRB.TAT. Panel C: Growth of O35E is compared to that of its tatC isogenic mutant strain, O35E.TC, carrying the plasmid pWW115 and pRB.TatC (contains a WT copy of tatC). Growth of the bro-2 isogenic mutant strain O35E.Bro is also shown. The results are shown as a composite image representative of individual experiments that were performed in duplicate on at least 3 separate occasions.
Figure 6Quantitative measurement of the β-lactamase activity produced by the WT isolate O35E and mutant strains. The β-lactamase activity of strains was measured using the chromogenic compound nitrocefin. Bacterial suspensions were mixed with a 250 μg/mL nitrocefin solution and the absorbance at 486 nm (A486) was immediately measured and recorded as time “0” (open bars). The A486 of the samples was measured again after a 30-min incubation at room temperature (black bars). Panel A: The β-lactamase activity of O35E is compared to that of the tatA mutant strain, O35E.TA, carrying the plasmid pWW115 (control), pRB.TatA (specifies a WT copy of tatA), and pRB.TAT (harbors the entire tatABC locus). Panel B: The β-lactamase activity of O35E is compared to that of the tatB mutant, O35E.TB, carrying the plasmid pWW115, pRB.TatB (specifies a WT copy of tatB), and pRB.TAT. Panel C: The β-lactamase activity of O35E is compared to that of the tatC mutant, O35E.TC, carrying the plasmid pWW115 and pRB.TatC (contains a WT copy of tatC). The strain O35E.Bro, which lacks expression of the β-lactamase BRO-2, was used as a negative control in all experiments in addition to the broth-only control. The results are expressed as the mean A486 ± standard error. Asterisks indicate that the reduction in the β-lactamase activity of mutants is statistically significant (P < 0.05) when compared to the WT strain O35E.
Figure 7Quantitative measurement of the β-lactamase activity of and recombinant strains. β-lactamase activity was measured using the chromogenic compound nitrocefin. Bacterial suspensions were mixed with a 250 μg/mL nitrocefin solution and the A486 was immediately measured and recorded as time “0” (open bars). The A486 of the samples was measured again after a 30-min incubation at room temperature (black bars). Panel A: The β-lactamase activity of M. catarrhalis O35E is compared to that of the bro-2 mutant, O35E.Bro, carrying plasmids pWW115, pTS.Bro, and pTS.BroKK. Panel B: The β-lactamase activity of H. influenzae DB117 carrying plasmids pWW115, pTS.Bro, and pTS.BroKK is compared. Sterile broth was used as a negative control in these experiments. The results are expressed as the mean ± standard error A486. Asterisks indicate that the reduction in the β-lactamase activity of strains lacking expression of BRO-2, or expressing a mutated BRO-2 that contains two lysine residues in its signal sequence instead of 2 arginines, is statistically significant (P < 0.05) when compared to bacteria expressing a WT copy of the bro-2 gene.
Figure 8Comparison of the putative TAT substrates identified in the genomes of strains ATCC43617and BBH18.
Strains and plasmids used in this study
| | | |
| O35E | WT isolate from middle ear effusion (Dallas, TX) | [ |
| O35E.TA | This study | |
| O35E.TB | This study | |
| O35E.TC | This study | |
| O35E.Bro | This study | |
| O12E | WT isolate from middle ear effusion (Dallas, TX) | [ |
| O12E.TC | This study | |
| McGHS1 | WT isolate from patient with respiratory infection (Toledo, OH) | [ |
| TTA37 | WT isolate from transtracheal aspirate (Johnson City, TN) | [ |
| V1171 | WT isolate from nasopharynx of a healthy child (Chapel Hill, NC) | [ |
| | | |
| DB117 | Host strain for cloning experiments with pWW115 | [ |
| | | |
| EPI300 | Cloning strain | Epicentre® |
| Illumina® | ||
| Plasmids | | |
| pCC1 | Cloning vector, camR | Epicentre® |
| Illumina® | ||
| pCC1.3 | pCC1-based plasmid containing kanR marker, camRkanR | [ |
| pRB.TatA.5 | Contains 886-nt insert specifying O35E | This study |
| pRB.TatB.1 | Contains 858-nt insert specifying O35E | This study |
| pRB.TatC.2 | Contains 1,018-nt insert specifying O12E | This study |
| pRB.TatC:kan | pRB.TatC.2 in which a kanR marker disrupts the | This study |
| pRB.Tat.1 | Contains 2,083-nt insert specifying O35E | This study |
| pRB.TatA:kan | pRB.Tat.1 in which a kanR marker disrupts the | This study |
| pRB.TatB:kan | pRB.Tat.1 in which a kanR marker disrupts the | This study |
| pRN.Bro11 | Contains 994-nt insert specifying O35E | This study |
| pRB.Bro:kan | pRN.Bro11 in which a kanR marker disrupts the | This study |
| pTS.BroKK.Ec | pRN.Bro11 in which 2 arginines in the signal sequence of the | This study |
| pWW115 | [ | |
| pRB.TatA | pWW115 into which the | This study |
| pRB.TatB | pWW115 into which the | This study |
| pRB.TatC | pWW115 into which the | This study |
| pRB.TAT | pWW115 into which the | This study |
| pTS.Bro | pWW115 into which the | This study |
| pTS.BroKK | pWW115 into which the | This study |